<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00869167</url>
  </required_header>
  <id_info>
    <org_study_id>07-052R</org_study_id>
    <nct_id>NCT00869167</nct_id>
  </id_info>
  <brief_title>Ramelteon for Insomnia Comorbid With Asthma</brief_title>
  <official_title>Ramelteon for Insomnia Comorbid With Asthma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Northwestern University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Takeda</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Northwestern University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial will test the efficacy and safety of ramelteon, a selective melatonin agonist, on
      patients with insomnia comorbid with asthma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects with insomnia comorbid with asthma will be randomized to placebo or ramelteon at
      night for 6 weeks.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <start_date>March 2008</start_date>
  <completion_date type="Actual">June 2009</completion_date>
  <primary_completion_date type="Actual">June 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pittsburgh Sleep Quality Index</measure>
    <time_frame>baseline and post-treatment (at end of 5 weeks)</time_frame>
    <description>The change in ISI and PSQI from baseline to end of study will be compared between the two groups.
PSQI has a score range of 0-21, with lower the number being less sleep disturbances ISI has a score range of 0-28, with lower score meaning less insomnia symptoms</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Insomnia Severity Index</measure>
    <time_frame>5 weeks</time_frame>
    <description>The change in ISI and PSQI from baseline to end of study will be compared between the two groups.
PSQI has a score range of 0-21, with lower the number being less sleep disturbances ISI has a score range of 0-28, with lower score meaning less insomnia symptoms</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Daytime Sleepiness (Epworth Sleepiness Scale)</measure>
    <time_frame>baseline and post-treatment (at end of 5 weeks)</time_frame>
    <description>Score of 0-24, with 24 being the most sleepy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Daytime Performance (Digit Symbol Substitution Test)</measure>
    <time_frame>baseline and post-treatment (at end of 5 weeks)</time_frame>
    <description>DSST tests the number of correct digit-symbol pairs that an individual can identify within an allotted period (60-90 sec). It test memory and concentration, among other parameters.
DSST score can range from 0-125, with 125 being the most number correct during the allotted time period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Daytime Lung Function (Peak Flow Monitoring) in Liter/Min</measure>
    <time_frame>baseline and during treatment period (during 5th week)</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">2</enrollment>
  <condition>Insomnia</condition>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>1: Ramelteon</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2: Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ramelteon</intervention_name>
    <description>melatonin agonist</description>
    <arm_group_label>1: Ramelteon</arm_group_label>
    <arm_group_label>2: Placebo</arm_group_label>
    <other_name>Rozerem</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Ages 18 - 60 with both insomnia and asthma.

          -  Insomnia:

               -  a complaint of difficulty initiating sleep, difficulty maintaining sleep, or
                  waking up too early or sleep that is chronically nonrestorative or poor in
                  quality,

               -  the sleep difficulty occurs despite adequate opportunity and circumstances for
                  sleep, and

               -  at least one form of daytime impairment related to the nighttime sleep difficulty
                  must be present. The sleep complaint should be present on most days for at least
                  3 months.

          -  Additional inclusion criteria include: a subjective TST &lt;6.5 h and a subjective SL &gt;
             45 min per night; a mean LPS &gt;20 min over 2 consecutive nights by polysomnography
             (neither night could have been &lt;15 min); a habitual bedtime between 10 PM and 1 AM;
             and ISI score &gt; 10 (based on 0-4 scale). LPS is defined as amount of time to the first
             10 minutes of continuous sleep.

          -  Asthma will be diagnosed based on suggestive clinical history and either

               -  airway hyperresponsiveness indicated by a 20% or greater decrease in FEV1 in
                  response to inhalation of methacholine at 8 mg/mL or less

               -  bronchodilator-responsive expiratory airflow limitation (if FEV1 &lt; 70% of
                  predicted value or &lt; 1.5 L, improving ≥200 mL and 12% in response to 180 µg of
                  albuterol aerosol). In addition to the above criteria, patients should have
                  well-controlled asthma as evidenced by ACQ score &lt; 1.5.

        Exclusion Criteria:

          -  Primary sleep pathology, other than insomnia as assessed by sleep history and
             confirmed by polysomnography to exclude significant sleep apnea (RDI &gt; 15), periodic
             leg movements (movement arousal index &gt; 15), REM behavior disorder; or circadian
             sleep-wake disorders

          -  History of cognitive or other neurological disorders;

          -  History of DSM-IV criteria for any major psychiatric disorder, including mania or
             alcohol or substance abuse;

          -  Depressive symptoms as assessed by the CES-D. Subjects with a score of 22 or greater
             indicates that the person may be suffering from a major depression and therefore, will
             be referred to their physician;

          -  Unstable or serious medical conditions;

          -  Current, or use within the past month, of psychoactive, hypnotic, stimulant or
             analgesic medications (except occasionally);

          -  Shift work or other types of self imposed irregular sleep schedules;

          -  Obesity (BMI &gt; 35 Kg/m2); or

          -  Pregnancy or desire to become pregnant during the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Brandon S Lu, MD, MS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Northwestern University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 19, 2009</study_first_submitted>
  <study_first_submitted_qc>March 24, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 25, 2009</study_first_posted>
  <results_first_submitted>June 28, 2011</results_first_submitted>
  <results_first_submitted_qc>May 27, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 29, 2012</results_first_posted>
  <last_update_submitted>April 26, 2013</last_update_submitted>
  <last_update_submitted_qc>April 26, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 1, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Northwestern University</investigator_affiliation>
    <investigator_full_name>Brandon Lu</investigator_full_name>
    <investigator_title>Physician</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
    <mesh_term>Sleep Initiation and Maintenance Disorders</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Ramelteon</title>
          <description>Participants with insomnia and asthma are randomized to Ramelteon 8mg and sleep hygiene for 5 weeks or to placebo and sleep hygiene for 5 weeks. Ramelteon or placebo to be taken within 30 minutes before</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Participants with insomnia and asthma are randomized to Ramelteon 8mg and sleep hygiene for 5 weeks or to placebo and sleep hygiene for 5 weeks. Ramelteon or placebo to be taken within 30 minutes before</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Ramelteon</title>
          <description>Participants with insomnia and asthma are randomized to Ramelteon 8mg and sleep hygiene for 5 weeks or to placebo and sleep hygiene for 5 weeks. Ramelteon or placebo to be taken within 30 minutes before</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Participants with insomnia and asthma are randomized to Ramelteon 8mg and sleep hygiene for 5 weeks or to placebo and sleep hygiene for 5 weeks. Ramelteon or placebo to be taken within 30 minutes before</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="2"/>
            <count group_id="B2" value="1"/>
            <count group_id="B3" value="3"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34.5" spread="9.2"/>
                    <measurement group_id="B2" value="38"/>
                    <measurement group_id="B3" value="35.6" spread="6.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Pittsburgh Sleep Quality Index</title>
        <description>The change in ISI and PSQI from baseline to end of study will be compared between the two groups.
PSQI has a score range of 0-21, with lower the number being less sleep disturbances ISI has a score range of 0-28, with lower score meaning less insomnia symptoms</description>
        <time_frame>baseline and post-treatment (at end of 5 weeks)</time_frame>
        <population>The 2 subjects in the Ramelteon group completed the study. The 1 subject in the placebo group did not complete the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Ramelteon</title>
            <description>Participants with insomnia and asthma are randomized to Ramelteon 8mg and sleep hygiene for 5 weeks or to placebo and sleep hygiene for 5 weeks. Ramelteon or placebo to be taken within 30 minutes before</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants with insomnia and asthma are randomized to Ramelteon 8mg and sleep hygiene for 5 weeks or to placebo and sleep hygiene for 5 weeks. Ramelteon or placebo to be taken within 30 minutes before</description>
          </group>
        </group_list>
        <measure>
          <title>Pittsburgh Sleep Quality Index</title>
          <description>The change in ISI and PSQI from baseline to end of study will be compared between the two groups.
PSQI has a score range of 0-21, with lower the number being less sleep disturbances ISI has a score range of 0-28, with lower score meaning less insomnia symptoms</description>
          <population>The 2 subjects in the Ramelteon group completed the study. The 1 subject in the placebo group did not complete the study.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Daytime Sleepiness (Epworth Sleepiness Scale)</title>
        <description>Score of 0-24, with 24 being the most sleepy</description>
        <time_frame>baseline and post-treatment (at end of 5 weeks)</time_frame>
        <population>The 2 subjects in the Ramelteon group completed the study. The 1 subject in the placebo group did not complete the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Ramelteon</title>
            <description>Participants with insomnia and asthma are randomized to Ramelteon 8mg and sleep hygiene for 5 weeks or to placebo and sleep hygiene for 5 weeks. Ramelteon or placebo to be taken within 30 minutes before</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants with insomnia and asthma are randomized to Ramelteon 8mg and sleep hygiene for 5 weeks or to placebo and sleep hygiene for 5 weeks. Ramelteon or placebo to be taken within 30 minutes before</description>
          </group>
        </group_list>
        <measure>
          <title>Daytime Sleepiness (Epworth Sleepiness Scale)</title>
          <description>Score of 0-24, with 24 being the most sleepy</description>
          <population>The 2 subjects in the Ramelteon group completed the study. The 1 subject in the placebo group did not complete the study.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.5" spread="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Daytime Performance (Digit Symbol Substitution Test)</title>
        <description>DSST tests the number of correct digit-symbol pairs that an individual can identify within an allotted period (60-90 sec). It test memory and concentration, among other parameters.
DSST score can range from 0-125, with 125 being the most number correct during the allotted time period.</description>
        <time_frame>baseline and post-treatment (at end of 5 weeks)</time_frame>
        <population>The 2 subjects in the Ramelteon group completed the study. The 1 subject in the placebo group did not complete the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Ramelteon</title>
            <description>Participants with insomnia and asthma are randomized to Ramelteon 8mg and sleep hygiene for 5 weeks or to placebo and sleep hygiene for 5 weeks. Ramelteon or placebo to be taken within 30 minutes before</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants with insomnia and asthma are randomized to Ramelteon 8mg and sleep hygiene for 5 weeks or to placebo and sleep hygiene for 5 weeks. Ramelteon or placebo to be taken within 30 minutes before</description>
          </group>
        </group_list>
        <measure>
          <title>Daytime Performance (Digit Symbol Substitution Test)</title>
          <description>DSST tests the number of correct digit-symbol pairs that an individual can identify within an allotted period (60-90 sec). It test memory and concentration, among other parameters.
DSST score can range from 0-125, with 125 being the most number correct during the allotted time period.</description>
          <population>The 2 subjects in the Ramelteon group completed the study. The 1 subject in the placebo group did not complete the study.</population>
          <units>Number correct</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8" spread="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Daytime Lung Function (Peak Flow Monitoring) in Liter/Min</title>
        <time_frame>baseline and during treatment period (during 5th week)</time_frame>
        <population>This measure was added during the study and no subjects completed the measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Ramelteon</title>
            <description>Participants with insomnia and asthma are randomized to Ramelteon 8mg and sleep hygiene for 5 weeks or to placebo and sleep hygiene for 5 weeks. Ramelteon or placebo to be taken within 30 minutes before</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants with insomnia and asthma are randomized to Ramelteon 8mg and sleep hygiene for 5 weeks or to placebo and sleep hygiene for 5 weeks. Ramelteon or placebo to be taken within 30 minutes before</description>
          </group>
        </group_list>
        <measure>
          <title>Daytime Lung Function (Peak Flow Monitoring) in Liter/Min</title>
          <population>This measure was added during the study and no subjects completed the measure.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Insomnia Severity Index</title>
        <description>The change in ISI and PSQI from baseline to end of study will be compared between the two groups.
PSQI has a score range of 0-21, with lower the number being less sleep disturbances ISI has a score range of 0-28, with lower score meaning less insomnia symptoms</description>
        <time_frame>5 weeks</time_frame>
        <population>The 2 subjects in the Ramelteon group completed the study. The 1 subject in the placebo group did not complete the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Ramelteon</title>
            <description>Participants with insomnia and asthma are randomized to Ramelteon 8mg and sleep hygiene for 5 weeks or to placebo and sleep hygiene for 5 weeks. Ramelteon or placebo to be taken within 30 minutes before bedtime</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants with insomnia and asthma are randomized to Ramelteon 8mg and sleep hygiene for 5 weeks or to placebo and sleep hygiene for 5 weeks. Ramelteon or placebo to be taken within 30 minutes before bedtime</description>
          </group>
        </group_list>
        <measure>
          <title>Insomnia Severity Index</title>
          <description>The change in ISI and PSQI from baseline to end of study will be compared between the two groups.
PSQI has a score range of 0-21, with lower the number being less sleep disturbances ISI has a score range of 0-28, with lower score meaning less insomnia symptoms</description>
          <population>The 2 subjects in the Ramelteon group completed the study. The 1 subject in the placebo group did not complete the study.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.5" spread="6.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Ramelteon</title>
          <description>Participants with insomnia and asthma are randomized to Ramelteon 8mg and sleep hygiene for 5 weeks or to placebo and sleep hygiene for 5 weeks. Ramelteon or placebo to be taken within 30 minutes before</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Participants with insomnia and asthma are randomized to Ramelteon 8mg and sleep hygiene for 5 weeks or to placebo and sleep hygiene for 5 weeks. Ramelteon or placebo to be taken within 30 minutes before</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Recruitment difficulties led to only 3 participants in the study. Only 2 participants finished the study.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Brandon Lu, M.D., M.S.</name_or_title>
      <organization>California Pacific Medical Center</organization>
      <phone>415-923-3421</phone>
      <email>lubs@sutterhealth.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

